TargEDys announces the publication of the first double-blind, randomized, placebo-controlled clinical trial showing Hafnia alvei's efficacy at an unprecedented level in weight loss and satiety
Jun 8, 2021
LONGJUMEAU, France, June 8, 2021 /PRNewswire/ -- The French biotech TargEDys specialized in breakthrough microbiome-based solutions announces the publication of its study conducted in 230 overweight adults supplemented for 12 weeks, confirming the efficacy of the precision probiotic Hafnia alvei HA4597® to improve weight loss, hip circumference reduction and metabolic parameters thanks to the action of the probiotic and its postbiotic ClpB on feeling of fullness. Mechanistic and preclini